ATTIVITA 'IN VITRO' DEL FLUCONAZOLE VS AMPFOTERICINA B NEI CONFRONTI DI CEPPI DI CRYPTOCOCCUS NEOFORMANS

Translated title of the contribution: Fluconazole vs amphotericin B: 'In vitro' activity against Cryptococcus neoformans

Research output: Contribution to journalArticle

Abstract

In this study the authors evaluated the 'in vitro' susceptibility of yeasts isolated to an antimycotic drug, fluconazole, in order to evaluate if its minimal inhibitory concentrations (MIC) was comparable to those of amphotericin B, by the means of the tube dilution method. A sample of 27 strains of Cryptococcus neoformans isolated from immunocompromised host was tested. The results show that fluconazole has a MIC90 value on C. neoformans (MIC90: 25 μg/ml) higher than amphotericin B (MIC90: 6.25 μg/ml). This suggests that fluconazole does not represent an alternative to amphotericin B for the treatment of the acute phase of cryptococcal infection. However, fluconazole proved to be more useful in the management of discharged patients, because it allowed their home treatment and the prevention of the relapses.

Original languageItalian
Pages (from-to)1089-1092
Number of pages4
JournalGiornale di Malattie Infettive e Parassitarie
Volume45
Issue number10-11
Publication statusPublished - 1993

Fingerprint

Cryptococcus neoformans
Fluconazole
Amphotericin B
Immunocompromised Host
Secondary Prevention
Yeasts
In Vitro Techniques
Therapeutics
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Parasitology

Cite this

@article{ed452da5965a4a0a8d76dd72755d2513,
title = "ATTIVITA 'IN VITRO' DEL FLUCONAZOLE VS AMPFOTERICINA B NEI CONFRONTI DI CEPPI DI CRYPTOCOCCUS NEOFORMANS",
abstract = "In this study the authors evaluated the 'in vitro' susceptibility of yeasts isolated to an antimycotic drug, fluconazole, in order to evaluate if its minimal inhibitory concentrations (MIC) was comparable to those of amphotericin B, by the means of the tube dilution method. A sample of 27 strains of Cryptococcus neoformans isolated from immunocompromised host was tested. The results show that fluconazole has a MIC90 value on C. neoformans (MIC90: 25 μg/ml) higher than amphotericin B (MIC90: 6.25 μg/ml). This suggests that fluconazole does not represent an alternative to amphotericin B for the treatment of the acute phase of cryptococcal infection. However, fluconazole proved to be more useful in the management of discharged patients, because it allowed their home treatment and the prevention of the relapses.",
keywords = "amphotericin B, C. neoformans, fluconazole",
author = "G. Michelone and C. Cavanna and G. Lombardi and R. Gulminetti",
year = "1993",
language = "Italian",
volume = "45",
pages = "1089--1092",
journal = "Giornale di Malattie Infettive e Parassitarie",
issn = "0017-0321",
publisher = "U T E T SpA",
number = "10-11",

}

TY - JOUR

T1 - ATTIVITA 'IN VITRO' DEL FLUCONAZOLE VS AMPFOTERICINA B NEI CONFRONTI DI CEPPI DI CRYPTOCOCCUS NEOFORMANS

AU - Michelone, G.

AU - Cavanna, C.

AU - Lombardi, G.

AU - Gulminetti, R.

PY - 1993

Y1 - 1993

N2 - In this study the authors evaluated the 'in vitro' susceptibility of yeasts isolated to an antimycotic drug, fluconazole, in order to evaluate if its minimal inhibitory concentrations (MIC) was comparable to those of amphotericin B, by the means of the tube dilution method. A sample of 27 strains of Cryptococcus neoformans isolated from immunocompromised host was tested. The results show that fluconazole has a MIC90 value on C. neoformans (MIC90: 25 μg/ml) higher than amphotericin B (MIC90: 6.25 μg/ml). This suggests that fluconazole does not represent an alternative to amphotericin B for the treatment of the acute phase of cryptococcal infection. However, fluconazole proved to be more useful in the management of discharged patients, because it allowed their home treatment and the prevention of the relapses.

AB - In this study the authors evaluated the 'in vitro' susceptibility of yeasts isolated to an antimycotic drug, fluconazole, in order to evaluate if its minimal inhibitory concentrations (MIC) was comparable to those of amphotericin B, by the means of the tube dilution method. A sample of 27 strains of Cryptococcus neoformans isolated from immunocompromised host was tested. The results show that fluconazole has a MIC90 value on C. neoformans (MIC90: 25 μg/ml) higher than amphotericin B (MIC90: 6.25 μg/ml). This suggests that fluconazole does not represent an alternative to amphotericin B for the treatment of the acute phase of cryptococcal infection. However, fluconazole proved to be more useful in the management of discharged patients, because it allowed their home treatment and the prevention of the relapses.

KW - amphotericin B

KW - C. neoformans

KW - fluconazole

UR - http://www.scopus.com/inward/record.url?scp=0027855505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027855505&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0027855505

VL - 45

SP - 1089

EP - 1092

JO - Giornale di Malattie Infettive e Parassitarie

JF - Giornale di Malattie Infettive e Parassitarie

SN - 0017-0321

IS - 10-11

ER -